Illumina (ILMN) is reducing its forecast for this year’s financial performance and cutting $100M in spending because China barred sales of its gene-sequencing machines, Jared Hopkins of Wall Street Journal reports. Illumina is lowering its 2025 adjusted earnings per share guidance to $4.50, the low end of the range of $4.50 to $4.65 a share given last month, its Chief Financial Officer Ankur Dhingra told the Journal. “We will protect our earnings, and we have the levers and the actions to protect our earnings,” Dhingra said.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target lowered to $90 from $127 at Baird
- Target reports Q4 beat, Walgreens reportedly near go-private deal: Morning Buzz
- Illumina doesn’t seem to be blocked from offering services in China, says Stifel
- Morning Movers: Target, Best Buy slipping after earnings as tariffs take effect
- China’s CM adds 10 American companies to ‘unreliable entry’ list, WSJ says
Questions or Comments about the article? Write to editor@tipranks.com